Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

This review of 36 head-to-head trials found for all adverse events, the ranking was as follows for general safety (high to low): atezolizumab, nivolumab, pembrolizumab, ipilimumab and tremelimumab. Nivolumab had the best safety profile in lung cancer.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news